Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.75 +6.1%	$1.41	$1.11 ▼ $5.00	$465.75M	1.77	1.50 million shs	2.30 million shs
GNLX Genelux	$2.46 +0.4%	$2.64	$1.60 ▼ $5.89	$92.83M	-0.33	191,576 shs	45,526 shs
KMDA Kamada	$6.87 -0.3%	$6.58	$4.74 ▼ $9.16	$394.89M	0.94	90,762 shs	28,119 shs
VERV Verve Therapeutics	$4.60 +8.5%	$4.53	$2.86 ▼ $9.31	$410.06M	1.82	1.89 million shs	5.24 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+5.10%	+12.24%	+18.71%	-5.71%	-58.96%
GNLX Genelux	-3.54%	-1.61%	-15.52%	-43.16%	-12.19%
KMDA Kamada	-0.86%	+0.88%	+3.77%	-0.29%	+31.49%
VERV Verve Therapeutics	-1.17%	+0.24%	-26.00%	-31.61%	-19.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5422 of 5 stars	3.5	1.0	2.7	3.3	0.6
GNLX Genelux	1.3024 of 5 stars	3.6	0.0	3.3	0.0	0.0
KMDA Kamada	4.1695 of 5 stars	3.4	5.0	2.8	1.7	3.1
VERV Verve Therapeutics	3.5466 of 5 stars	4.5	2.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	432.57% Upside
GNLX Genelux	3.20	Buy	$17.75	621.54% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	113.49% Upside
VERV Verve Therapeutics	3.00	Buy	$25.75	459.78% Upside

Current Analyst Ratings Breakdown

Latest GNLX, AUTL, KMDA, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/15/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $24.00
4/15/2025	VERV Verve Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/15/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $39.00
4/14/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $25.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
3/31/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/25/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	51.69	N/A	N/A	$0.64 per share	2.73
GNLX Genelux	$8K	11,603.51	N/A	N/A	$0.73 per share	3.37
KMDA Kamada	$167.24M	2.36	$0.38 per share	17.90	$4.25 per share	1.62
VERV Verve Therapeutics	$59.61M	6.88	N/A	N/A	$7.31 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	8/14/2025 (Estimated)
GNLX Genelux	-$28.30M	-$0.88	N/A	N/A	N/A	N/A	-105.05%	-80.16%	8/13/2025 (Estimated)
KMDA Kamada	$8.28M	$0.29	24.54	21.47	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)
VERV Verve Therapeutics	-$200.07M	-$2.11	N/A	N/A	N/A	-807.65%	-35.23%	-27.65%	8/14/2025 (Estimated)

Latest GNLX, AUTL, KMDA, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest GNLX, AUTL, KMDA, and VERV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/5/2025	KMDA Kamada	--	$0.20		3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
GNLX Genelux	N/A	6.47	6.47
KMDA Kamada	N/A	4.84	2.73
VERV Verve Therapeutics	N/A	13.05	13.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
GNLX Genelux	37.33%
KMDA Kamada	20.38%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
GNLX Genelux	9.30%
KMDA Kamada	36.10%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
GNLX Genelux	10	37.74 million	31.33 million	Not Optionable
KMDA Kamada	360	57.48 million	36.73 million	Optionable
VERV Verve Therapeutics	110	89.14 million	68.32 million	Optionable

GNLX, AUTL, KMDA, and VERV Headlines

Recent News About These Companies

Heart Disease Could Be a Goner When These New Drugs Arrive

May 29 at 6:47 PM | msn.com

Verve Therapeutics to Participate in Upcoming Investor Conferences

May 28 at 7:00 AM | globenewswire.com

Experimental drug promising to bring down bad cholesterol by up to 69% completes early stage trial

May 26 at 11:36 AM | theprint.in

Verve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

Northern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 25, 2025 | marketbeat.com

Wall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"

May 24, 2025 | marketbeat.com

Groundbreaking treatment for bad cholesterol on the horizon? This single-use drug shows some promise

May 24, 2025 | cnbctv18.com

Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.

May 23, 2025 | msn.com

HC Wainwright Has Optimistic Outlook of VERV FY2025 Earnings

May 23, 2025 | marketbeat.com

Millennium Management LLC Sells 1,105,050 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

May 23, 2025 | marketbeat.com

FY2025 EPS Estimate for Verve Therapeutics Lifted by Analyst

May 23, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for VERV FY2026 Earnings?

May 22, 2025 | marketbeat.com

Research Analysts Offer Predictions for VERV FY2026 Earnings

May 22, 2025 | americanbankingnews.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

Point72 Asset Management L.P. Buys New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 21, 2025 | marketbeat.com

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks

May 20, 2025 | finance.yahoo.com

Tema Etfs LLC Invests $503,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 20, 2025 | marketbeat.com

Cantor Fitzgerald Analysts Raise Earnings Estimates for VERV

May 20, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Positive Outlook for VERV Earnings

May 20, 2025 | marketbeat.com

Q3 EPS Forecast for Verve Therapeutics Lifted by Analyst

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX, AUTL, KMDA, and VERV Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.75 +0.10 (+6.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 -0.02 (-1.37%)

As of 06:21 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Genelux NASDAQ:GNLX

$2.46 +0.01 (+0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.46 0.00 (0.00%)

As of 07:21 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Kamada NASDAQ:KMDA

$6.87 -0.02 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.89 +0.02 (+0.29%)

As of 04:04 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Verve Therapeutics NASDAQ:VERV

$4.60 +0.36 (+8.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.57 -0.03 (-0.65%)

As of 07:27 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time